Last Updated on December 31, 2023 by The Health Master
Download NPPA notification No. S.O. S.O. 195(E) dt 11-01-2023, the link is given below: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of17 scheduled formulations vide vide S.O. 195(E) dt 11-01-2023 based on the decision of 107th Authority meeting dated 11.01.2023.
This price fixation followed the decision of the 107th Authority meeting on January 11, 2023.
In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO
1499(E) dated 30th March, 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods
and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table
| Sl. No. | Name of the Scheduled Formulation | Dosage form and strength | Unit | Ceiling Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) |
| 1 | Tenecteplase | Injection 40mg/vial | 1 Vial | 44939.44 |
| 2 | Tenecteplase | Injection 30mg/vial | 1 Vial | 32917.76 |
| 3 | Bendamustine hydrochloride | Injection 100 mg/vial | 1 Vial | 4411.75 |
| 4 | Entecavir | Tablet 0.5mg | 1 Tablet | 75.31 |
| 5 | Leuprolide acetate | Powder for injection 22.5 mg | 1 Vial | 15233.93 |
| 6 | Leuprolide acetate | Powder for injection 11.25mg | 1 Vial | 8289.17 |
| 7 | Leuprolide acetate | Powder for injection 3.75 mg | 1 Vial | 2776.00 |
| 8 | Metoprolol | Modified Release Tablet 100 mg | 1 Tablet | 13.37 |
| 9 | Metoprolol | Tablet 100 mg | 1 Tablet | 9.93 |
| 10 | Propranolol | Tablet 20mg | 1 Tablet | 2.85 |
| 11 | Clopidogrel | Tablet 150 mg | 1 Tablet | 18.27 |
| 12 | Carbimazole | Tablet 20mg | 1 Tablet | 12.37 |
| 13 | Acyclovir | Tablet 800mg | 1 Tablet | 33.59 |
| 14 | Lenalidomide | Capsule 25 mg | 1 Capsule | 260.66 |
| 15 | Medroxyprogesterone acetate | Injection 150mg/mL | 1 ML | 258.42 |
| 16 | Midazolam | Nasal Spray 1.25mg/ actuation | 1 ML | 193.37 |
| 17 | Midazolam | Nasal Spray 0.5 mg/actuation | 1 ML | 71.29 |
Note:
(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO 2013.
The manufacturer shall issue a price list in Form–V from the date of the Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of the production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.
Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
National List of Essential Medicines (NLEM)
NPPA revised Ceiling price of 111 scheduled formulations: January 2023
NPPA fixes retail price of 12 formulations: January 2023
NPPA revised Retail Price of 93 scheduled formulations: January 2023
NPPA fixes Retail Price of 4 scheduled formulations: January 2023
NPPA fixes retail price of 36 formulations: January 2023
NPPA fixes Retail Price of 10 formulations: December 2022
Drug recall: Rifampin Capsules recalled due to this reason
Fraud in MBBS admissions: High Court stays acquittal
Nutraceutical industry trends will rule the year
Govt to introduce incentive scheme to boost R&D by pharma industry:…
USFDA gives tentative approval Acalabrutinib capsules, 100 mg
NPPA revised Ceiling price of 111 scheduled formulations: January 2023
NABL asks laboratories to make fresh registrations in new NABL portal
Drug alert: 70 out of 1375 samples declared as NSQ in December 2022
USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
